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preponderance of locally advanced tumors, local control and 
overall survival are encouraging. 
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Purpose/Objective: To asses the clinical utility of 18F-FDG 
PET-CT in patients with advanced head and neck squamous 
cell carcinoma (HNSCC), considering the prognostic value in 
staging study and the response to radiotherapy (RT) 
treatment with or without chemotherapy.  
Materials and Methods: Radiotherapy planning was 
performed with 18F-FDG PET-CT in 28 patients (p) diagnosed 
of HNSCC between august 2009 and august 2013. 
Male/Female: 23/5. Mean age: 60 years (range: 49-74). 
Location primary tumor: larynx 11 (39%), oropharynx 6 (21%), 
hypopharynx 6 (21%) and oral cavity 5 (18%). Clinical tumor 
stage: III 4 (14%); IVa 23 (82%); IVb: 1 (4%). They were 
treated at our Center with curative intent using RT (mean 
dosis 6943 cGy, range 6600-7000): with or without 
chemotherapy (concurrent n=25 and induction n=14). 
Minimum follow-up 12 months. Response was assessed by 
18F-FDG PET-CT at least 8 weeks after completion of 
radiotherapy (mean 15 weeks, range 8-45). Maximum 
standard uptake value (SUVmax) of primary tumor (T) and 
lymph nodes (N) in staging PET were measured and compared 
in both groups of patients: those with complete response at 
treatment (CR) and those with no complete response (noCR). 
Sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy (Acc) were 
calculated in the response 18F-FDG PET-CT.  
Results: Basal PET mean SUVmax for T and N was 19,48 and 
10.50 respectively. The response 18F-FDG PET-CT showed 
complete metabolic response in 19 p (68%), partial response 
in 5 p (18%) and progression disease in 4 p (14%), with 
evidence of nodal disease in 4 p (14%) (mean SUVmax 4,89) 
and residual tumor in 8 p (29%) (mean SUVmax 8,34). In the 
follow-up period 17 p had no recurrence. Sensitivity, 
specificity, PPV, NPV and Acc of response PET-CT was 88%, 
95%, 88%, 95% and 93% for primary tumor, and 67%, 91%, 50%, 
95% and 88% for nodal disease. Overall survival (OS) and 
disease-free survival (DFS) at 2 years were 79% and 64%, 
respectively. Mean SUVmax of T in CR group and noCR were 
19,33 and 19,68 respectively. Mean SUVmax of N were 9,31 
and 12,41 respectively. We did not find differences 
statistically significant between nodal or primary tumor 
SUVmax and overall survival (p=0,9173 for T, p=0,3165 for N).  
Conclusions: 18F-FDG PET-CT is a useful method for assessing 
response after radical chemoradiotherapy in advanced 
HNSCC, showing a high negative predictive value for primary 
tumor and lymph nodes. In our cohort, higher primary tumor 
and nodal SUVmax was not associated with lower rates of 
survival. Multi-institutional trials are required to establish 
stronger conclusion on this matter. 
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Purpose/Objective: To report initial results of a prospective 
clinical trial aimed to assess instrumental swallowing function 
in nasopharynx and oropharynx cancers after radio or 
chemoradiotherapy using intensity-modulated radiotherapy 
(IMRT). 
Materials and Methods: IMRT was delivered aiming to spare 
the swallowing organ at risk (SWOARs) for Stage II-IV naso and 
oropharynx cancer. Objective instrumental assessment 
included Videofluoroscopy (VFS), Fiberoptic Endoscopic 
Evaluation of Swallowing (FEES) and Oro-Pharyngeal-
Esophageal Scintigraphy (OPES) at baseline and 1,6 and 12 
months after radiotherapy. Dysphagia parameters scores 
were calculated and reported at each exam both after liquid 
(L) and semi-liquid (SL) bolus intake: pre-swallowing 
penetration, aspiration, pharyngeal transit time (PTT) and 
hypopharyngeal retention index (HPRI) 
Results: Overall 20 patients (6 Nasophaynx and 14 
Oropharynx) completed treatment and instrumental 
assessment at 1 month. Correlations between the pre and 
post-treatment changes in HPRI scores resulted statistically 
significant both at FEES-L (p=0,021) and SL (p=0,02) and at 
VFS-L (p=0,008) and SL (p=0,005). Moreover significant 
relationships between baseline and 1 month HPRI score at 
FEES-L and FEES-SL (p=0,005) as well as at VFS-L and VFS-SL 
(p<0,001), were observed. Differently, PTT resulted not 
significantly affected by radiotherapy (p>0,2). Only few 
patients experienced pre-swallowing penetration (1 patient 
with base of tongue cancer at FEES-L and SL) and aspiration 
(1 patient with nasopharynx cancer at OPES-L and FEES-SL) 
after radiotherapy 
Conclusions: Our early results showed that radiotherapy 
significantly increased the post-swallowing HPRI. Longer 
follow-up will be necessary to evaluate if the increase of 
HPRI is related to an high risk to develop late aspiration. 
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Purpose/Objective: It was previously shown that SUVmax of 
pretreatment 18-Fluordesoxyglucose PET/CT (FDG-PET) of 
the primary in locally advanced lung cancer patients was 
associated with higher risk of distant failure (DF) (V.J. Nair et 
al., 2014). The following analysis tries to find similarities in 
case of locally advanced, non-metastatic patients with 
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squamous cell carcinoma of the head and neck (SCCHN) who 
are treated with combined chemoradiation (CRT). The aim 
was to find a potential SUVmax threshold to predict risk of 
distant failure (DF), local failure (LF) and regional failure 
(RF). This may help identifying patients at risk and subject 
them to intensified treatment. 
Materials and Methods: In a study conducted between 2008 
and 2014, 21 patients were prospectively analyzed for 
dynamics of tumor hypoxia during CRT. This consisted of 
radiotherapy in IMRT-technique (5 x 2 Gy/week up to 70 Gy) 
and concurrent platinum-based chemotherapy (weeks one, 
four and seven). Additionally the patients received 
pretreatment FDG-PET and MRI scans of the head and neck 
and FMISO-PET. The SUVmax determined in the FDG-PET/CT 
were used for further analysis to find a correlation with DF, 
LF and RF. In follow-up (FU) we performed regular CT and 
MRI scans of the head and neck and lung. For correlation 
analysis we used Spearman coefficient. We performed 
statistical analysis with SPSS Statistics 21 (IBM). 
Results: Between 08/2008 and 04/2014, 22 patients (three 
women and nineteen men) with histologically proven SCCHN 
were recruited, mean ECOG score 1, average FU time was 
30.6 months (0.6-63 months). Two patients developed DF (9.1 
%), five patients developed local (22.3 %) and two patients 
regional failure (9.1 %), respectively. The correlation 
coefficient between DF, LF, RF and FDG-SUVmax was -0.061, -
0.26 and 0.06, respectively. Median SUVmax in FDG-PET was 
14.4 (n=20). Average FDG-SUVmax of patients with any 
treatment failure (DF, LF and RF) was 15.2 (n=7).  
Conclusions: There could not be shown a significant 
correlation between DF, LF or RF and SUVmax in FDG-PET. But 
still our data shows that above an FDG-SUVmax of 14.4, a 
larger proportion of patients showed treatment failure, so 
there may be a higher risk for failure above that threshold. It 
remains an interesting question whether a larger cohort and 
a longer FU- time might show a correlation. There is need for 
further investigation.  
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Purpose/Objective: Tumor hypoxia is commonly related to a 
poorer prognosis and to higher radioresistance. The degree of 
reoxygenation during radiotherapy contributes to improved 
therapy success. 18-Fluoromisonidazole PET/CT (FMISO-PET) 
non-invasively allows visualizing tumor hypoxia and its 
dynamics under chemoradiation (CRT) of squamous cell 
cancer of the head and neck (SCCHN). There is little evidence 
for the relation between hypoxia and changes in blood 
oxygenation determined by hemoglobin (HB) and 
erythropoietin (EPO) levels in blood. Matter of interest is also 
the relation between these biomarkers with metastasis-free 
survival (MFS) and loco-regional control (LRC). 
Materials and Methods: Between 2008 and 2014 we 
prospectively analyzed the dynamics of tumor hypoxia during 
CRT in 21 patients at our center. This consisted of 
radiotherapy in IMRT-technique (5 x 2 Gy/week up to 70 Gy) 
and concomitant platinum-based chemotherapy (weeks one, 
four and seven). Additionally the patients received 
pretreatment FDG-PET and MRI scans of the head and neck 
and FMISO-PET for hypoxic imaging (in week 'zero'). The 
hypoxia was further evaluated in week 2 and 5 with two more 
FMISO-PET scans. EPO and HB levels were also determined 
parallel to hypoxic imaging. Tumor hypoxia in FMISO-PET was 
defined as SUVmax(tumor)/SUVmean(muscle). In follow-up (FU) 
we performed regular CT and MRI scans of the head and neck 
and lung. For correlation analysis we used Spearman 
coefficient. We performed statistical analysis with SPSS 
Statistics 21 (IBM). 
Results: Between 08/2008 and 04/2014, 22 patients (three 
women and nineteen men) with histologically proven SCCHN 
were recruited, mean ECOG score 1, average FU time was 
30.6 months (0.6-63 months). 4 patients developed DF (18.2 
%). Average SUVmax(tumor)/SUVmean(muscle) was 1.9/1.6/1.3 
(weeks 0/2/5; n=22/20/17). Average SUVmax in FDG-PET was 
14.4 (n=20). Average HB-concentrations were 14.1/12.6/10.9 
g/dl (weeks 0/2/5). Average EPO-concentrations were 
determined in 9 patients (7.3 mU/ml). Correlation coefficient 
between DF and FMISO- SUVmax(tumor)/SUVmean(muscle) is -
0.3/-0.4/-0.4 (in weeks 0/2/5). Correlation coefficient 
between HB and EPO, and between HB and FMISO is -0.02 and 
0.02/-0.3/-0.4 (weeks 0/2/5), respectively. 
Conclusions: There could not be shown any significant 
correlation between tumor hypoxia and HB and/or EPO, nor 
were there any correlations between distant failure and 
SUVmax(tumor)/SUVmean(muscle). There is need for further 
data acquisition.  
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Purpose/Objective: In cases of head and neck cancer (HNC) 
radiotherapy, custom-designed oral prostheses are sometimes 
used to depress the tongue or push the hard palate away 
from the clinical target volume (CTV) and intended to reduce 
side-effects to surrounding organs at risk (OAR). We 
evaluated whether the use of custom-designed oral 
prostheses improved daily setup precision of HNC.  
Materials and Methods: The custom-designed oral prostheses 
were made of resin to fit each patient’s oral cavity. The 
upper and lower parts and inter-space bar of the prostheses 
mate together by occlusal pressure to immobilize and 
displace the hard palate or tongue to reduce unnecessary 
radiation dose. Nine locally advanced HNC patients 
(prostheses group) at our hospital were treated from June 
2012 to September 2013 by three-dimensional external 
radiotherapy using custom-designed oral prostheses, 
immobilized with a thermoplastic mask. These patients 
(oropharyngeal: 4; tongue: 3; and maxillary: 2; histologically, 
7 squamous cell carcinoma (SqCC), and 2 lymphomas) 
received total doses of 50.4 to 68.4Gy (mean 58.8Gy) in daily 
fractions of 1.8 to 2.0 Gy. The seven patients with SqCC 
received concurrent chemotherapy of CDDP and 5-FU. Each 
